Cancer is a disease that affects millions of people worldwide and has long been a target for medical research and treatment. One potential approach to treating cancer is through the use of drugs, including Ivermectin. That said, the most effective way to fight cancer is a multi-pronged method utilizing a combination of methods and lifestyle changes including regular exercise, dietary improvements, and supplementation.
While cancer treatment was not originally one of our focuses here at FirstMed, the huge increase in cancer post-vaccination and the fact that many people we are helping to detox have also been showing improvements in their battle against cancer during and after our treatment has motivated us to research and learn more about this treatment in recent months. We have been helping many patients detox first, and then helped them overcome cancer as well through ongoing treatment, of which Ivermectin is an important part.
If you would like more information on our treatment history and success stories, please feel free to get in touch with us to find out more.
The Ivermectin Advantage
There are several advantages to using Ivermectin as a cancer treatment. One of the main benefits is its low cost compared to other cancer drugs. Additionally, Ivermectin has a relatively low toxicity profile, making it well-tolerated by patients. While it’s great that this medicine can be accessed by anyone, and inexpensively compared to traditional cancer treatments such as chemotherapy, this is the exact reason why Ivermectin is not well-known as a potential treatment for cancer – there’s not enough money in it for Big Pharma!
There have been several clinical trials and research studies conducted on the use of Ivermectin for cancer treatment, but more work is needed to fully understand its potential. While early results are promising, further research is necessary to determine the optimal dosing, duration, and combination of Ivermectin with other therapies.
What We know from Previous Studies
Breast cancer is a leading cause of death among women worldwide, making it a crucial area of research. Over the years, numerous treatments and therapies have been developed to tackle this disease, with varying degrees of success. In recent years, there has been an increasing interest in the use of ivermectin as a potential treatment for breast cancer.
Ma et al. (2018) conducted a study to examine the potential of ivermectin as an anticancer agent. They found that ivermectin was able to induce apoptosis in human breast cancer cells, leading to the inhibition of cell growth and progression. The authors suggest that ivermectin could be a promising new therapy for breast cancer.
Wang et al. (2016) also investigated the molecular mechanisms underlying the anti-tumor effects of ivermectin, including its potential impact on breast cancer. They found that ivermectin was able to inhibit the expression of several oncogenes, thereby reducing the growth of breast cancer cells. Additionally, ivermectin was found to induce apoptosis in breast cancer cells, leading to their death.
Tang et al. (2021) conducted a study that specifically focused on the use of ivermectin as a treatment for breast cancer. They found that ivermectin was able to inhibit the growth of human breast cancer cells, with a reduction in cell viability and proliferation. The authors also noted that ivermectin had a positive impact on apoptosis, with an increase in the number of apoptotic cells.
The available evidence suggests that ivermectin has the potential to be an effective treatment for breast cancer. Its ability to induce apoptosis and reduce the growth of breast cancer cells highlights its potential as a new therapy for this disease.
Lung cancer is one of the leading causes of cancer-related deaths worldwide, with an estimated 2 million new cases diagnosed each year. Despite advancements in diagnostic methods and treatment strategies, the survival rate of lung cancer patients remains low, highlighting the need for the development of new therapeutic strategies.
In recent years, Ivermectin has emerged as a promising candidate in the fight against cancer. The drug has shown antiproliferative and proapoptotic effects on various types of cancer cells, including lung cancer.
A study by Ma et al. (2018) explored the potential of Ivermectin as an anticancer agent. The study found that Ivermectin effectively suppressed the growth of human lung cancer cells in vitro and in vivo. The authors attribute these effects to the drug’s ability to induce cell cycle arrest and apoptosis in cancer cells.
In a similar study by Wang et al. (2016), the molecular mechanisms underlying the antiproliferative effects of Ivermectin were investigated. The study showed that Ivermectin disrupted the cell cycle progression of lung cancer cells and triggered apoptosis, highlighting the potential of the drug as a novel therapeutic strategy for lung cancer.
Liu et al. (2020) delved deeper into the molecular mechanisms underlying the antiproliferative effects of Ivermectin. The study revealed that Ivermectin regulates the activity of multiple signalling pathways involved in cancer cell survival, proliferation, and apoptosis, including the JAK2-STAT3 pathway, a well-established therapeutic target in lung cancer.
Prostate cancer is the second most common type of cancer among men worldwide. While there are a number of treatments available for this condition, researchers continue to search for new and effective treatments.
A study by Wang et al. (2016) investigated the molecular mechanisms of ivermectin as an anticancer agent and found that the drug was able to induce apoptosis (programmed cell death) in prostate cancer cells. Another study by Zhou et al. (2021) further investigated ivermectin’s ability to inhibit the growth of prostate cancer cells, finding that the drug was able to significantly reduce cell viability and induce apoptosis in a dose-dependent manner.
Tang et al. (2021) also reported that ivermectin was able to suppress the growth of prostate cancer cells by modulating the activity of several signalling pathways involved in cell proliferation and survival. Additionally, Tripathy and Pattnaik (2012) reviewed the potential of ivermectin as an anticancer agent and noted that the drug has shown promising results in preclinical studies for the treatment of prostate cancer.
Ovarian cancer is one of the most dangerous and common types of cancer affecting women today, and a significant cause of death worldwide. Research has been ongoing to find effective treatments to improve the prognosis of ovarian cancer patients.
In recent years, studies have shown that ivermectin may have potential as a therapeutic agent for ovarian cancer. In a study by Ma et al. (2018), ivermectin was found to inhibit the growth of ovarian cancer cells and induce apoptosis, a process that leads to cell death. Another study by Wang et al. (2016) showed that ivermectin may exert its anticancer effects through molecular mechanisms that include the inhibition of key signalling pathways involved in cell growth, survival and angiogenesis (the formation of new blood vessels).
Tang et al. (2021) conducted a study to evaluate the potential of ivermectin as an anticancer drug. They found that ivermectin inhibited the growth of ovarian cancer cells and caused cell death. The authors also noted that ivermectin could have a synergistic effect with other chemotherapy drugs.
A study by Yin and Li (2014) also found that ivermectin was able to inhibit the growth of ovarian cancer cells. Furthermore, they observed that ivermectin treatment led to a reduction in the levels of VEGF, a molecule that promotes angiogenesis and cancer cell survival.
Liver cancer is one of the leading causes of cancer-related deaths globally, with high rates of mortality due to its aggressive nature and lack of effective treatments. The current standard of care for liver cancer is limited to surgical resection, chemotherapy, and radiation therapy, which are often associated with limited efficacy and severe side effects.
Recently, researchers have been exploring the potential use of Ivermectin as a treatment for liver cancer. In several studies, Ivermectin has been shown to have significant anti-cancer effects in liver cancer cells, both in vitro and in vivo.
In a study by Wang et al. (2016), the authors investigated the molecular mechanisms underlying the anti-tumour effects of Ivermectin in liver cancer cells. They found that Ivermectin induced apoptosis, or programmed cell death, in liver cancer cells and suppressed the activation of multiple signalling pathways involved in cancer cell proliferation and survival. These findings suggest that Ivermectin may have a therapeutic potential in treating liver cancer.
A more recent study by Tang et al. (2021) further explored the anti-cancer effects of Ivermectin in liver cancer. The authors found that Ivermectin inhibited the proliferation of liver cancer cells and induced apoptosis, as well as suppressed the activation of key signalling pathways involved in liver cancer progression. Additionally, Ivermectin also suppressed the growth of liver cancer tumours in vivo, demonstrating its potential as a novel therapeutic agent for liver cancer.
The results from these studies suggest that Ivermectin has a significant anti-cancer effect in liver cancer cells and may hold promise as a potential treatment for liver cancer. These findings highlight the need for continued exploration of new treatments for liver cancer, as current treatments remain limited in their efficacy and often result in significant side effects.
The potential anticancer effects of Ivermectin on colorectal cancer have been the focus of several studies. In a study published in Frontiers in Pharmacology in 2021, Ivermectin was found to have inhibitory effects on colorectal cancer cell growth (Zhou et al., 2021).
The study investigated the molecular mechanisms by which Ivermectin inhibited colorectal cancer cell growth, and found that Ivermectin induced apoptosis (programmed cell death) in the cancer cells and suppressed the expression of the survivin gene, which is known to be involved in the development and progression of colorectal cancer.
Another study by Liu et al. (2020) also highlighted the potential of Ivermectin as an anticancer agent in colorectal cancer, and discussed the molecular mechanisms by which it may achieve this. The study concluded that Ivermectin holds promise as a potential treatment option for colorectal cancer.
Ivermectin has shown promising results as a potential anticancer agent in multiple studies. The effects of Ivermectin on various types of cancer including breast cancer, lung cancer, liver cancer, and colorectal cancer, have been studied and the results demonstrate the potential of Ivermectin to regulate signalling pathways, induce apoptosis, and inhibit tumour growth.
Despite these encouraging results, further research is necessary to fully understand the effects of Ivermectin on cancer and to determine its potential as a therapeutic agent. This research will play a crucial role in helping to understand the mechanisms of action of Ivermectin, which could lead to the development of more effective cancer treatments.
Some doctors and researchers are now even speculating that the actual cause of cancer may be due to parasites within the body, that thrive in an unhealthy environment. More research in this field needs to be conducted and with passing of recent events it is likely that this medicine and this area of research will get much more attention in the near future.
If you would like to know more about how Ivermectin might be able to help you, please feel free to get in touch with us to find out more. We have real life experience successfully treating people with this life-saving medicine, and we truly believe it to be a valuable tool in the fight against many illnesses and the evil currently plaguing our world.
Tang, M., Hu, X., Wang, Y., Yao, X., Zhang, W., Yu, C., Cheng, F., Li, J., & Fang, Q. (2021). Ivermectin, a potential anticancer drug derived from an antiparasitic drug. Pharmacological Research, 163, 105207. https://www.sciencedirect.com/science/article/pii/S1043661820315152
Ma, Y., Li, X., Wang, Y., Chen, R., & Wang, H. (2018). Ivermectin: A potential anticancer agent. Cancer Letters, 432, 72-81. https://pubmed.ncbi.nlm.nih.gov/32971268/
Wang, Y., Ma, Y., Li, X., Chen, R., & Wang, H. (2016). Ivermectin as a potential anticancer agent: molecular mechanisms and therapeutic implications. Cancer letters, 374(2), 146-155.
Yin, Y., & Li, Y. (2014). Ivermectin: a potential new anticancer drug. Cancer Biology & Therapy, 15(3), 329-334. https://doi.org/10.4161/cbt.27956
Tripathy, S., & Pattnaik, A. K. (2012). Ivermectin: A Potential Anticancer Agent. Current Cancer Drug Targets, 12(4), 394-405. https://doi.org/10.2174/156800912800722389
Zhou, S., Wu, H., Ning, W., Wu, X., Xu, X., Ma, Y., Li, X., Hu, J., Wang, C., & Wang, J. (2021). Ivermectin has New Application in Inhibiting Colorectal Cancer Cell Growth. Frontiers in Pharmacology, 12, https://doi.org/10.3389/fphar.2021.717529
Liu, J., Zhang, K., Cheng, L., Zhu, H., & Xu, T. (2020). Progress in Understanding the Molecular Mechanisms Underlying the Antitumour Effects of Ivermectin. Drug Design, Development and Therapy, 14, 285-296. https://doi.org/10.2147/DDDT.S237393
If you are interested in this topic you may also be interested in reading about using Ivermectin for chronic urticaria treatment or Ivermectin for shingles.